Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Maucherat

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Nuclear Medicine|December 16, 2020
Effective Management of 177Lu-DOTA0-Tyr3-Octreotate ExtravasationBruno Maucherat, Nicolas Varmenot, Vincent Fleury, et al.
European Journal of Hybrid Imaging|June 7, 2021
COVID-19 vaccination may cause FDG uptake beyond axillary areaVincent Fleury, Bruno Maucherat, Daniela Rusu, et al.
Clinical Nuclear Medicine|July 14, 2020
Long-term Trace of Radiation Pneumonitis With 18F-FluoroestradiolAgnès Morel, Bruno Maucherat, Sophie Chiavassa, et al.
Clinical Nuclear Medicine|June 8, 2022
Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 VaccinationLoic Ah-Thiane, Ludovic Ferrer, Bruno Maucherat, et al.
Clinical Nuclear Medicine|April 15, 2022
Is Glucagon Administration Compatible With FDG PET/MRI?Bruno Maucherat, Roshanack Movassaghi, Vincent Fleury, et al.
The Prostate|December 15, 2018
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changesMatthieu Barbaud, Mathieu Frindel, Ludovic Ferrer, et al.
The Prostate|August 18, 2019
Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-makingCaroline Rousseau, Maelle Le Thiec, Ludovic Ferrer, et al.
Cancers|June 13, 2020
Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal CancerMaelle Le Thiec, Aude Testard, Ludovic Ferrer, et al.
Clinical Nuclear Medicine|December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Nuclear Medicine|December 16, 2020
Effective Management of 177Lu-DOTA0-Tyr3-Octreotate ExtravasationBruno Maucherat, Nicolas Varmenot, Vincent Fleury, et al.
European Journal of Hybrid Imaging|June 7, 2021
COVID-19 vaccination may cause FDG uptake beyond axillary areaVincent Fleury, Bruno Maucherat, Daniela Rusu, et al.
Clinical Nuclear Medicine|July 14, 2020
Long-term Trace of Radiation Pneumonitis With 18F-FluoroestradiolAgnès Morel, Bruno Maucherat, Sophie Chiavassa, et al.
Clinical Nuclear Medicine|June 8, 2022
Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 VaccinationLoic Ah-Thiane, Ludovic Ferrer, Bruno Maucherat, et al.
Clinical Nuclear Medicine|April 15, 2022
Is Glucagon Administration Compatible With FDG PET/MRI?Bruno Maucherat, Roshanack Movassaghi, Vincent Fleury, et al.
The Prostate|December 15, 2018
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changesMatthieu Barbaud, Mathieu Frindel, Ludovic Ferrer, et al.
The Prostate|August 18, 2019
Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-makingCaroline Rousseau, Maelle Le Thiec, Ludovic Ferrer, et al.
Cancers|June 13, 2020
Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal CancerMaelle Le Thiec, Aude Testard, Ludovic Ferrer, et al.
Clinical Nuclear Medicine|December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Pageof 1